BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23784973)

  • 1. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2021 Feb; 96(2):258-269. PubMed ID: 33368476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waldenström macroglobulinemia.
    Gertz MA
    Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenstrom macroglobulinemia: prognosis and management.
    Oza A; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenström macroglobulinemia.
    Kasi PM; Ansell SM; Gertz MA
    Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
    Merchionne F; Procaccio P; Dammacco F
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Blood; 2007 Jun; 109(12):5096-103. PubMed ID: 17303694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
    Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
    J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.